BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

...eligible for autologous stem cell transplant. The anti-CD38...
...Universal Flu Vaccine (M-001, bvx-m001) Darzalex, daratumumab (JNJ-54767414, humax-cd38) Prasinezumab...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

...other two are anti-GM-CSF mAb otilimab (MOR103) and anti-CD38...
BioCentury | Aug 6, 2020
Regulation

GSK first across finish line in closely watched BCMA race

...relapsed and refractory MM who progressed on an immunomodulatory agent, a proteasome inhibitor and an anti-CD38...
BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

...antibody AMG 424, and will return its rights to Xencor Inc. (NASDAQ:XNCR). The mAb targeting CD38...
BioCentury | Jul 14, 2020
Deals

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

...royalties. Sanofi plans to test CD38KO, a CD38-knockout NK cell therapy, in combination with its anti-CD38...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...or refractory MM in patients who have received at least four prior therapies, including an anti-CD38...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

...in July 2019. European approval of subcutaneous Darzalex The EC approved a subcutaneous formulation of anti-CD38...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

...strategy for re-entering oncology, and the company believes new data strengthen the case for the CD38...
...a new combination with carfilzomib and dexamethasone that point to a potential advantage over other CD38...
...47% and led to a complete response of 40%. In contrast, Darzalex daratumumab, the blockbuster CD38...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...NASDAQ, raising $114.5 million at an $818 million valuation. Similar to Alphamab, I-Mab has a CD38-targeted...
BioCentury | May 13, 2020
Product Development

May 12 Quick Takes: Skyhawk, Merck expand deal; plus Sanofi’s Sarclisa and clinical updates drive gains for Gamida, CymaBay

...target from Merck, plus royalties. Sarclisa meets in MM Phase III Sanofi (Euronext:SAN; NASDAQ:SNY) said anti-CD38...
Items per page:
1 - 10 of 242